High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin—but not with treatment of physician’s choice—in the EMBRACE study

BACKGROUND: Eribulin, a nontaxane synthetic inhibitor of microtubule dynamics, is widely used to manage locally advanced or metastatic breast cancer (MBC). Eribulin has demonstrated immunomodulatory activity on the tumour microenvironment. Baseline neutrophil-to-lymphocyte ratio (NLR), a marker of i...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Breast Cancer
Autors principals: Miyoshi, Yasuo, Yoshimura, Yuta, Saito, Kenichi, Muramoto, Kenzo, Sugawara, Michiko, Alexis, Karenza, Nomoto, Kenichi, Nakamura, Seigo, Saeki, Toshiaki, Watanabe, Junichiro, Perez-Garcia, Jose Manuel, Cortes, Javier
Format: Artigo
Idioma:Inglês
Publicat: Springer Japan 2020
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7297864/
https://ncbi.nlm.nih.gov/pubmed/32133606
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12282-020-01067-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars